[{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Huashan Hospital","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Huashan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Huashan Hospital \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Huashan Hospital \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Boehringer Ingelheim GmbH | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH | Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH | Incyte Corporation"},{"orgOrder":0,"company":"Michael Hopp","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase IV","graph3":"Michael Hopp","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael Hopp \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Michael Hopp \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Region Skane","sponsor":"Swedish Lung Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Region Skane","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Region Skane \/ Swedish Lung Cancer Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Region Skane \/ Swedish Lung Cancer Study Group"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ecog-Acrin Cancer Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Ecog-Acrin Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ecog-Acrin Cancer Research Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ecog-Acrin Cancer Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Afatinib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
